Skip to content
Adrienne Monson – Lifestyle
Author:
NextCure
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
June 4, 2026
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
June 1, 2026
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
May 4, 2026
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
April 21, 2026
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
March 31, 2026